Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rachel Zentner

Psychiatry Hastings, NE Medical Doctor

NPI 1669813549 CMS profile 552961

835 S Burlington Ave Ste 108, Hastings, NE 68901

Open in the dashboard

General payments

$5,646

473 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rachel Zentner of Hastings, NE is reported in the CMS Open Payments database as having received $5,646 across 473 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $420 27
2024 General $614 38
2023 General $768 69
2022 General $1,264 120
2021 General $1,104 96
2020 General $605 46
2019 General $873 77

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rachel Zentner
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Rachel Zentner were reported at $420. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Rachel Zentner Psychiatry median Middle half National median
2019 $873 $184 $59–$605 $163
2020 $605 $119 $36–$372 $114
2021 $1,104 $143 $43–$576 $132
2022 $1,264 $153 $50–$590 $149
2023 $768 $170 $56–$651 $160
2024 $614 $179 $57–$673 $164
2025 $420 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,444 126 payments
  2. Janssen Pharmaceuticals, Inc $886 98 payments
  3. Alkermes, Inc. $623 70 payments
  4. ITI, Inc. $550 26 payments
  5. Otsuka America Pharmaceutical, Inc. $519 36 payments
  6. Teva Pharmaceuticals USA, Inc. $350 26 payments
  7. Allergan Inc. $328 30 payments
  8. Sunovion Pharmaceuticals Inc. $220 17 payments
  9. Neurocrine Biosciences, Inc. $167 10 payments
  10. Ironshore Pharmaceuticals Inc. $128 7 payments
  11. Other $430 27 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,606 472 payments
  2. Education $40 1 payment
Products named General payments · program years 2019–2025
  1. VRAYLAR Neuroscience $1,269 112 payments
  2. INVEGA SUSTENNA $886 98 payments
  3. ARISTADA Cns $623 70 payments
  4. ARISTADA Cns $623 70 payments
  5. ARISTADA INITIO $600 69 payments
  6. CAPLYTA $526 25 payments
  7. INVEGA TRINZA $479 55 payments
  8. ARISTADA Cns $473 49 payments
  9. ARISTADA Cns $473 49 payments
  10. VRAYLAR Neuroscience $432 40 payments
  11. Other $2,439 187 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 80 drugs

Part D claims

5,678

Median for Psychiatry: 574

Drug cost

$1,832,604

Median for Psychiatry: $27,624

Branded share of claims

30.4%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Austedo Deutetrabenazine Brand 75 $497,420
Ingrezza Valbenazine Tosylate Brand 40 $342,405
Vraylar Cariprazine Hcl Brand 159 $209,428
Invega Sustenna Paliperidone Palmitate Brand 58 $193,485
Abilify Asimtufii Aripiprazole Brand 14 $78,399
Rexulti Brexpiprazole Brand 58 $71,146
Risperdal Consta Risperidone Microspheres Brand 49 $61,442
Caplyta Lumateperone Tosylate Brand 35 $58,108
Trintellix Vortioxetine Hydrobromide Brand 89 $44,533
Auvelity Dextromethorphan Hbr/Bupropion Brand 34 $44,016

The 10 drugs with the highest cost, of 80 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$35,250

Medicare's payments for the services billed

Medicare patients

127

Average age 63

Services billed

737

86 women, 41 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Depression 65%
Arthritis 42%
Diabetes 28%
COPD 20%
Osteoporosis 19%
Chronic kidney disease 17%
Alzheimer's or dementia 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $373
$373 159 —
CAPLYTA
  • ITI, Inc. $48
$48 35 —
JORNAY PM
  • Ironshore Pharmaceuticals Inc. $48
$48 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $32
$32 58 —
COBENFY
  • E.R. Squibb & Sons, L.L.C. $23
$23 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

473 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Nebraska

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record